Clinical Data Another LAG-3 setback as Regeneron drug fails phase 3 trial PharmaphorumRegeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.OncologyRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) Pharmaphorum Regeneron’s LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studiesNext: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
